In colon cancer cells, initial reduction in ERK signaling by BRAFV600E inhibitor treatment decreases the phosphatase activity of CDC25C, which in turn results in elevated EGFR phosphorylation [22]. Here, CDC25C is linked to malignant colon neoplasm.